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ABSTRACT  
The paramyxovirus replication machinery comprises the viral large (L) and phospho-(P) proteins 
in addition to the nucleocapsid (N) protein that encapsidates the single stranded RNA genome. 
Common to paramyxovirus N proteins is a C-terminal tail (Ntail), which contributes to docking 
of the polymerase complex to the genome through defined interaction domains. The central Ntail 
section is structurally disordered and thought to provide spatial flexibility required for productive 
interaction of the polymerase with the encapsidated viral genome, but its mechanistic role and 
relevance for successful virus replication is untested. Focusing initially on members of the 
morbillivirus genus, a series of Measles virus (MeV) and Canine distemper virus (CDV) N 
proteins were generated with internal deletions in the unstructured tail section. N proteins with 
large tail truncations remained bioactive in mono- and polycistronic minireplicon assays and 
supported efficient replication of recombinant viruses. Bioactivity of Ntail mutants extended to 
N proteins derived from highly pathogenic Nipah virus (NiV), a member of the henipavirus 
genus. To probe an effect of Ntail truncations on viral pathogenesis, recombinant CDVs were 
analyzed in a lethal CDV/ferret model of morbillivirus disease. The recombinant viruses 
displayed different stages of attenuation ranging from ameliorated clinical symptoms to complete 
survival of infected animals, depending on the molecular nature of the Ntail truncation. 
Reinfection of surviving animals with pathogenic CDV revealed robust protection against a 
lethal challenge. The highly attenuated was genetically stable after extensive ex vivo passaging 
and recovery from infected animals. Mechanistically, gradual viral attenuation coincided with 
stepwise-altered viral transcriptase activity in infected cells. These results identify the central 
Ntail section as a determinant for viral pathogenesis and establish a novel platform to engineer 
gradual virus attenuation for next-generation paramyxovirus vaccine design. 
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1 INTRODUCTION 
1.1  Paramyxoviridae family 
        Mononegavirales (non-segmented, negative sense RNA viruses) comprises eight major 
families, which include human and animal pathogens: 1) Bornaviridae (for example- Borna 
disease virus (BDV)), 2) Filoviridae (for example-Ebola virus, Marburg virus), 3) 
Paramyxoviridae (for example- Measles virus (MeV), Canine distemper virus (CDV), Mumps 
virus (MuV), Henipaviruses (Hendra virus (HeV) and Nipah virus (NiV)), 4) Pneumoviridae (for 
example- human respiratory syncytial virus (RSV)), 5) Rhabdoviridae (for example- rabies virus, 
vesicular stomatitis virus (VSV)), 6) Mymonaviridae (Sclerotimonavirus), 7) Nyamiviridae (for 
example- Nyavirus), 8) Sunviridae (Sunshine virus). Paramyxoviridae family is further divided 
into different genera including Rubulaviruses (for example- MuV), Respiroviruses, 
Henipaviruses (for example- NiV), Morbilliviruses (for example- MeV and CDV), and 
Avulaviruses, Aquaparamyxoviruses and Ferlaviruses (1) 
 
Members of the Paramyxoviridae family are mostly pathogenic, contagious and infect a 
variety of hosts through the respiratory route. Paramyxoviridae virions are generally 
pleiomorphic in shape and 150-350nm in diameter. Paramyxoviruses infect cells through fusion 
with the plasma membrane. They induce cell-cell fusion, thereby creating giant multinucleated 
cells (syncytia) (2) 
 
Paramyxoviridae genomes are similar in gene order and intergenic junctions separate the 
genes. Some differences in these genomes are their different attachment proteins. Respiroviruses 
and Rubulaviruses have hemagglutinin-neuraminidase [HN] attachment protein, while 
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Morbilliviruses have hemagglutinin [H] and Henipaviruses have G as their attachment protein in 
different genera of Paramyxoviridae subfamily. The envelope of the MeV virion contains two 
glycoproteins: F or the fusion protein, which promotes fusion of the viral and host cell 
membranes, and H-which is the viral attachment protein. The matrix protein (M protein) forms 
an electron-dense layer underlying the viral bilayer. M regulates MeV RNA synthesis and 
particle assembly by interacting with the nucleoprotein [N] as well as the lumenal tails of H and 
F (2-4). 
 
All members of paramyxoviridae share a common mechanism of RNA synthesis. Viral 
RNA synthesis occurs in the cytoplasm and involves the N, phosphoprotein (P) and large protein 
(L). The viral polymerase (RNA-dependent RNA-polymerase/RdRp) is a hetero-oligomer 
composed of the L and P proteins. L performs all of the enzymatic activities while P acts as a co-
factor. P chaperones newly synthesized N protein (N0) to the RNA template during replication 
(5-7), binds L, and also interacts with the nucleocapsid/ribonucleoprotein (RNP) template to 
mediate transcription and replication, respectively (8).  
 
Polymerization initiation can be performed in different ways for different single stranded 
RNA viruses. There are two kinds of different mechanisms: de novo and primer-dependent 
initiation. In addition to MeV, VSV and RSV demonstrates de novo synthesis. In case of VSV 
and RSV, the polymerase preloads with the first two and three nucleotides respectively (9, 10). 
Some positive sense RNA viruses use a primer-dependent initiation mechanism, while a cap 
snatching mechanism is used by Influenza. The endonuclease cleaves capped RNAs to generate 
the primers that initiate viral RNA transcription (11), but in case of replication it uses a de novo 
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mechanism (12). The switch mechanism between transcription and replication is not fully 
understood. For example, the RSV polymerase can initiate polymerization at either +1 or +3 
position (13). It has also been proved that the regulation of transcription and replication also 
depends on host proteins as shown with the leader region of MeV polymerase (14). 
MeV P encodes two additional nonstructural proteins- the C and V proteins. Alternative 
translation initiation or RNA editing, respectively, expresses these proteins. By inhibiting the 
interferon signaling, C and V interfere with the innate host immune response (3, 4). The C 
protein interferes with IFN induction via its regulatory role in viral RNA synthesis. Viral RNAs 
accumulate in cells infected with MeV-(ΔC) virus, possibly stimulating host innate immune 
responses (15, 16). V protein is formed by the insertion of a non-templated guanine nucleotide at 
a precise location, called an “editing site,” which generates an mRNA which differs from that of 
P with an altered ORF downstream of the editing site. Thus, due to this specific mechanism, the 
N-terminal domain of P and V are identical, whereas their C-terminal domains are unique (17). 
The V protein blocks the JAK–STAT signalling pathway by interacting with STAT1 and STAT2 
(18).  
 
Some members of the Paramyxoviridae family are responsible for pediatric morbidity 
and mortality. Vaccines have been successful in providing protection from some 
paramyxoviruses, such as MeV and MuV.  MeV is one of the most readily transmitted 
communicable diseases infecting children. There is an effective Measles-Mumps-Rubella 
vaccine recommended by the World Health Organization (WHO). WHO recommends two doses 
of the MMR vaccine- the primary dose is administered to children within 9-15 months of age and 
the booster dose is given between 2-5 years of age. Exposure to either wild type or attenuated 
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MeV in form of the MMR vaccine delivers a lifetime protection mediated by antibodies 
delivered from memory B cells (19, 20). However, natural boosting is required to maintain 
protection since antibodies induced by the vaccine wane over time. 
 
The highly efficacious MMR vaccine has currently failed to eliminate MeV worldwide. 
A herd immunity of 95% is required in order to prevent MeV endemic outbreaks (21) because 
MeV typically reemerges first when vaccination coverage in a population drops (22). On the 
other hand, a fraudulent article reports that the MMR vaccine is linked to the development of 
autism in 1998 and this has led to many anti-vaccination campaigns (23). Although the research 
has been proven flawed (24, 25), many parents are still scared to vaccinate their child.  
 
Unfortunately, no vaccine exists for the newly emerging paramyxovirses like NiV (26), 
despite major research efforts. The Hendra vaccine has been shown to be cross-protective 
against NiV infection in the non-human primate model (27). A NiV-specific monoclonal 
antibody has been shown to be protective in non-human primates (28). The efficacy of some 
vaccines (such as CDV vaccine) still remains questionable (29).  Thus, there is an urgent need 
for the development of new and highly efficient strategies to prevent infections and provide 
potent therapeutic treatment to treat many outbreaks that still occur.  
 
1.2 Morbillivirus genus 
1.2.1 Measles virus (MeV) 
For many Morbilliviruses, the tropism and tissue distribution is found to be similar. There 
are three main receptors used by MeV for attachment and cell entry. The first is CD46, a 
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ubiquitously expressed receptor on all nucleated cells. Its physiological function is to protect the 
cells from attack of invading pathogens by regulating complement activation and also regulates 
innate and acquired immune responses. The vaccine and laboratory-adapted MeV strains use 
CD46 for attachment and entry (30, 31). The second is the signaling lymphocyte activation 
molecule (SLAM/CD150), expressed on immune cells like the activated T and B cells, 
macrophages and mature dendritic cells (DC’s). SLAM functions by interacting with another 
SLAM molecule on the adjacent cell and undergoes its tyrosine phosphorylation to produce T-
helper cytokines: interleukin (IL)-4 and IL-13 (32, 33). The functions and distribution of SLAM 
receptor proves the lymphotropic and immunosuppressive nature of MeV. The third receptor is 
Nectin-4/PVRL4, which is expressed on epithelial cells located on the basolateral side of the 
airway epithelium (34, 35). Other receptors that have been identified are DC-specific ICAM-3 
grabbing non-integrin (DC-SIGN) and neuronal cell-specific Neurokinin-1 (NK-1) (36). 
 
MeV is transmitted via the respiratory route and infects resident DC’s and alveolar 
macrophages (AM’s) in the lungs. Infected DCs and AM’s transport MeV to the draining lymph 
nodes where they infect the lymphocytes via the SLAM receptor. A transient fever at 3-6 days 
post MeV infection coincides with primary viremia. The virus is largely lymphotropic and 
spreads through lymphoid organs and tissues such as spleen or thymus as well as the liver, skin, 
tonsils and respiratory mucosal surfaces. This causes the secondary viremia (37). High fever co-
incides with viremia and other symptoms such as cough, coryza, Kopliks’s spots occur 10-12 
days post infection. The trademark maculopapular rash occurs later at around 14-15 days post 
infection. This occurs because of the infiltration of cytokines into sites of MeV replication (38).  
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Nectin-4/PVRL4 receptor is involved in MeV spread through virus infected immune cells 
to the basolateral side of the airway epithelium. This finally results in virus shedding (39).  A 
large number of infected cells present in the respiratory tract cause the symptoms such as 
coughing and sneezing and sometimes pneumonia. This allows the virus to undergo host-to-host 
transmission, which contributes to MeV outbreaks (40). 
 
MeV causes suppression of the adaptive immune response. Some studies show decreased 
IL-12 and increased IL-4, IL-10 production that changes Th1 response to a prolonged Th2 
response. The infection also causes T cell non-responsiveness due to virus-induced immaturity of 
infected DC’s (41-45). MeV infection also suppresses the proliferation of lymphocytes (46). This 
unresponsiveness can be caused by contact of lymphocytes with the viral glycoprotein on MeV 
virions or MeV-infected cells, independently of virus replication in lymphocytes. It may also be 
caused due to the H protein interaction with SLAM on lymphocytes (47). At the same time, MeV 
induces strong immune responses that confer lifelong immunity (48). This contradiction is 
known as the ‘measles paradox’. The lymphocyte numbers generally return to normal within a 
week after the disappearance of MeV clinical symptoms, while the immune suppression extends 
for several weeks to months. It is therefore believed that MeV immune suppression mainly 
results from depletion of immune cell subsets, but this is in turn masked by the rapid 
proliferation of MV-specific lymphocytes (49).  
 
Additionally, MeV-induced autoimmune demyelination of neurons in the brain, known as 
acute disseminated encephalomyelitis (ADEM), can occur within 2 weeks after the onset of 
infection. Progressive measles inclusion body encephalitis (MIBE) can arise after the virus has 
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cleared from the host (50, 51). Another fatal disease of the central nervous system (CNS) is the 
subacute sclerosing panencephalitis (SSPE). SSPE can occur several years later after infection 
and is caused by demyelination and presence of MeV in neuronal cells of the brain (52). As of 
today, it is unclear how MeV infects neurons within the CNS (53) and circulating virus specific 
antibodies alone fail to clear the virus.  
 
1.2.2 Canine distemper virus (CDV) 
      CDV, another member of Morbillivirus genus, is a common cause of morbidity and 
mortality in unvaccinated domestic or feral dogs. It also affects other carnivores such as cats, 
lions, tigers, bears and is also very common in some endangered species and other aquatic and 
terrestrial carnivores (54-60) 
The use of SLAM receptor is common to the Morbillivirus genus. CDV uses dog SLAM 
as its principal receptor for viral entry. Like MeV, CDV also spreads by aerosol and causes 
primary and secondary viremia. CDV infection is also mainly lymphotropic. It causes clinical 
symptoms such as fever, rash, conjunctivitis, pneumonitis, and neurological diseases. In the case 
of CDV infection, acute encephalomyelitis is often observed. Also, symptoms like hyperceratosis 
of footpads and epithelium of the nasal tract are very often observed. CDV shows the same 
disease profile in ferrets as MeV causes in humans. Although, the live-attenuated CDV vaccines 
are fully apathogenic in dogs, they can cause severe clinical distemper in sensitive species such 
as black-footed ferrets or other carnivores (29).  
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Animal models: 
CDV disease is very severe and leads to 100% mortality in ferrets after intranasal 
infection. Therefore, the lethal CDV-ferret animal model (29) is the most commonly used small-
animal model system for the members of the Morbillivirus genus. It is used as the surrogate 
model as there is no other suitable animal model for MeV except the macaques, which are 
inaccessible, expensive and do not show all the classic symptoms except mild rash and transient 
lymphopenia (61, 62). Rodent models like mice expressing transgenic CD46 (63, 64) or cotton 
rats (65) do not replicate the exact MeV pathogenesis and virulence.  
 
1.3 Henipavirus genus 
1.3.1 Nipah virus (NiV) 
Henipaviruses have a broad species tropism including flying fox species, fruit bat species 
which are the reservoirs for the viruses in this genus (66). NiV is a highly lethal zoonotic 
paramyxovirus. The natural infection occurs in pigs and is amplified in them. The first outbreak 
occurred in peninsular Malaysia in 1998. NiV first infected pig farmers working in contact 
with pigs and this was the primary cause of the outbreak. Numerous cases of encephalitis 
among pig farmers were reported. The pigs had been infected through consumption of 
contaminated fruit from infected fruit bats (Pteropus spp.). Pig-human transmission occured 
accidentally. Infection in humans is found to be severe (67-71) Subsequent deadlier outbreaks 
occured in Bangladesh and India. Human-to-human transmission in home or hospital settings 
has also been documented (72, 73) High case fatality rate by NiV infection emphasizes the 
urgent need for prophylactic or therapeutic medical treatments. 
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Ephrin-B2 or B3 is known to be the functional receptor for Henipavirus genus and is 
found on arteries, arterioles and capillaries in various organs. The viruses attach to the receptor 
and infect host cells using the attachment G and the fusion F proteins (74, 75). The common 
symptoms include fever, headache, drowsiness, hypertension, and encephalitis. Atypical 
pneumonia and acute severe respiratory syndrome is also common (17). No vaccines are 
available to treat NiV infection and therefore, it is very important to develop a safe and 
efficacious vaccine (76). 
 
1.4 Replication machinery of Paramyxoviridae members 
Negative-sense viruses (NSV) contain RNP complexes, which are formed when the 
genomic as well as the antigenomic RNA are encapsidated by the viral N protein. 
Paramyxoviruses forms a characteristic  herringbone structure in EM images. RNP’s act as the 
template for both transcription and replication. In addition, P and L proteins are also involved in 
both transcription and replication, but the two processes are different (77). 
 
Figure 1: Schematic representation of MeV phosphoprotein (not drawn to scale) 
having a N-terminal (PNT) and a C-terminal (PCT) including a tetramerization domain 
(PMD) and a C-terminal RNP binding domain (P-XD). 
 
MeV P protein consists of 400-600amino acids and its physiological oligomer is the 
tetramer. It is very highly phosphorylated protein. P is the polymerase cofactor and links the L 
polymerase to the RNP template. It comprises of L (polymerase) binding site and N binding site. 
1 230 
PMD 
304 376 
XD 
459 507 
PNT PCT 
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The MeV P protein is comprised of an N-terminal (PNT) domain (1-230aa) and a C-terminal 
(PCT) domain (231-507aa) as shown in figure 1. PNT chaperones newly synthesized N protein 
(N0) to the RNA template during replication. PNT also holds N monomers in an open 
conformation and prevents premature oligomerization (7). PCT includes a tetramerization 
domain (PMD) and a C-terminal RNP binding domain (P-XD) that mediates high-affinity 
interactions with the N protein (78-80).  
 
MeV L protein is a 2200 AA (220 to 250 kDa) protein and its structural organization and 
location of individual enzymatic activities are very well understood. The L protein contains all 
enzymatic (capping, methylation, adenylation, RNA binding) activities associated with mRNA 
synthesis and genome replication. The L protein is comprised of six domains- domain II 
considered to be associated with RNA binding, domain III harbors the predicted catalytic center 
for phosphodiester bond formation and domains V and VI postulated to mediate capping 
functions (81-83).  
 
Viral replication of Paramyxoviridae takes place in the host cell cytoplasm after viral 
entry and uncoating of the genome into the cell. For both transcription and replication, the viral 
polymerase complex initiates polymerization at the 3’ end of the RNP (84). N wraps around 6 
nucleotides of RNA and follows the rule of six. These genomes are of negative polarity and thus 
the viral RdRp transcribes into mRNA first, which gets capped and polyadenylated by the L 
protein. 3’ and a 5’ noncoding leader and trailer regions, respectively, flank the coding regions of 
the non-segmented genome. The viral polymerase promoter is present in the noncoding regions 
and gene start/stop signals are in the intergenic junctions that separate each of the individual 
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genes. For both transcription and replication, the viral polymerase complex exclusively initiates 
polymerization at the 3’ end of the N encapsidated RNA (84).  In the case of transcription, the 
MeV RdRp complex scans and polymerizes along the template until it encounters the 
polyadenylation signal to produce monocistronic N mRNA at position 55. The complex then re-
initiates to transcribe the next gene. Some premature falling of the polymerase complex with 
increase in template length occurs and creates a gradient of gene expression in which the genes 
that are closer to the promoter are more abundant. The likelihood of premature detachment 
increases with template length, resulting in lower mRNA levels of downstream genes, which 
creates the transcription gradient. When enough N protein is produced to encapsidate the nascent 
RNA, the RdRp complex switches from transcription to replication. In replication mode, the 
MeV RdRp complex ignores the intergenic junctions in between genes. It produces a complete 
plus polarity copy of the genome (antigenome), which is concurrently encapsidated by N (8). 
The polymerase initiates antigenome production from the leader region. The RdRp complex does 
not recognize any non-encapsidated RNA (85) 
 
1.5 Nucleoprotein 
N proteins from Paramyxoviridae members are approximately 500 or more amino acids 
in length. Their function is to encapsidate the viral genomic RNA to form RNP. N does not bind 
to any cellular RNA or viral mRNAs. Unassembled N interacts with P called the No-P complex 
that involves the interaction between Ncore and PNT. This complex helps in guiding N to newly 
synthesized genomic RNA prevents N from nonspecifically binding cellular RNA. However, 
when used in heterologous systems, and in the absence of other viral proteins, N will bind 
cellular RNAs and form structures that are similar to authentic viral RNP (86, 87).   
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Figure 2: Cryo-EM structure of the MeV Ncore RNA nucleocapsid at near-atomic 
resolution (From: Irina Gutsche et al. Science 2015;348:704-707) 
(A) Schematic of MeV N (navy blue, NTD arm; blue, NTD; salmon, CTD; yellow, CTD arm). 
The same color code (with RNA in green) is used for the rest of the figure. (B and C) Isosurface 
representation of the cryo-EM 3D reconstruction of the helical nucleocapsid: (B) front view, (C) 
cutaway view. 
 
Recently, a 4.3Å resolution structure of the MeV helical nucleocapsid was solved 
using cryo-electron microscopy. This structure clearly defined the interactions between MeV N 
and the encapsidated RNA. The RNA thread winds around the MeV nucleocapsid: inside the 
cavity between the N-terminal domain (NTD) of the N-core and the C-terminal domain (CTD) of 
the N-core as shown in figure 2. A hinge region between NTD and CTD may allow for an open-
closed transition during RNP formation (88). 
 13 
 
Figure 3: Schematic representation of Paramyxoviridae nucleoproteins (not drawn 
to scale) having a conserved N-core and a flexible N-tail. 
 
All paramyxoviridae N proteins have a conserved amino terminal domain, known as N-
core, and a flexible and poorly conserved, intrinsically disordered and is highly flexible C-
terminal domain, known as N-tail (as shown in figure 3). MeV-N features a 400-residue amino-
terminal RNA-binding core (N-core) and a 125-residue carboxy-terminal tail domain (N-tail). 
The presence or absence of the N-tail affects the overall spatial organization of the RNP. It has 
been demonstrated that complete removal of the N-tail by trypsin digestion leads to complete 
loss of RdRp bioactivity. This is due to the decrease in the MeV N:RNA diameter and pitch that 
causes extreme rigidity (89). Decrease in flexibility due to the decrease in the diameter may be 
affecting the RdRp processivity and this may lead to the loss of RdRp bioactivity. 
 
Some studies show that the N-tail is essential for RdRp-mediated transcription and 
replication (90-93). There are conserved microdomains in N-tail (box 1-3) that are important for 
MeV replication. Box 1 (401-420a.a) binds to an uncharacterized nucleoprotein receptor (NR) 
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(94). Box 2 (488-499a.a), also known as the molecular recognition element i.e. MoRE interacts 
with the X-domain (XD) in the C-terminal of the P protein (91). This interaction is thought to 
stabilize the RNP template which is very important for allowing the polymerase complex to 
progress along the template for transcription and replication of the virus (80). It is a reversible 
phenomenon since the interaction has to be made and broken to allow the polymerase to progress 
during transcription and replication unless P remains static and L moves (95). Box 3 (517-
525a.a) stabilizes the MoRE-XD interaction (80, 96, 97). Furthermore, box 3 is thought to 
interact with the M protein (3) and with the heat shock proteins to facilitate efficient genome 
replication and incorporation of the genome into nascent particles (3, 98, 99).  
 
In a recent study, it was demonstrated that the MeV nucleocapsid protein tail domain is 
dispensable for polymerase activity. The truncated N-tail mutant (N-Δ86) restored the 
polymerase complex activity in a minigenome system. In order to test the bioactivity of the 
central section of the N-tail region, a plasmid mutant was designed and the conserved N-tail 
boxes were kept intact. This MeV N-tail mutant showed higher polymerase activity as compared 
to its standard but the recombinant mutant virus was not replication competent. By qPCR 
analysis, it was also shown that the presence of fully N-tail truncated mutant affected the stability 
of RdRp binding to RNP’s and that the likelihood of abortive separation of RdRp from the RNP 
template was increased in the absence of the N-tail MoRE domain. Thus, it was concluded that 
the MoRE:P-XD interaction is required to prevent catastrophic premature polymerase 
termination (80). 
 
In another study, the placement of the MoRE near the MeV N-tail terminus was shown 
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not to be important for virus replication and that MORE could be placed in the MeV conserved 
N-core. It was also confirmed that MORE is not important for loading of RdRp onto and/or 
RdRp progression along the RNP template (100). A regulatory role of the central section seems 
to exist and to define that was the main objective of the following study.  
 
Figure 4: Schematic representation of MORE-XD interaction in the presence of 
Morbilliviral N-standard and a central section truncated mutant. 
The main hypothesis of my Ph.D work was that the central section of the morbilliviral N-
tail is not important for virus replication and would be responsible for a specific polymerase 
regulatory role. This is shown in the figure 4, which shows that by truncating the central section 
of the N-tail, the morbilliviral replication would not be affected. 
 
In the subsequent chapters, a detailed overview of a minireplicon/ bioluminescent 
reporter assay systems is given as they are very commonly used to study gene expression as well 
as other cellular components and events that are involved in gene regulation. 
 
Advantages: Such virus-free reporter assay systems have also been widely used for screening 
antiviral drugs. Many compounds have been tested for potential antiviral activity using reporter 
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assay systems (89). Various luciferase reporters are used for a high-throughput screening (HTS) 
protocol design that can identify paramyxovirus-speciﬁc, orthomyxovirus-speciﬁc, or broadly 
specific compounds in a single assay system (101). Furthermore, prior to rescuing a recombinant 
virus from its full-length cDNA, a minireplicon reporter system is used to verify the validity of 
the rescue protocol experimental process (102).  
  
1.6 Monocistronic Minireplicon / Bioluminescent assays 
Minireplicon/Bioluminescent assays depend on enzymes called luciferases. Luciferases 
or luciferase enzymes are classified as oxidative enzymes found in several species that enable the 
organisms that express them to eradiate bioluminescence. These enzymes emit a photon and in 
turn allow the oxidation of luciferins to form oxyluciferin. There are many structurally diverse 
luciferin substrates. Many bioluminescence-producing organisms are isolated in order to utilize 
them for this assay, including luciferases from fireflies and various marine organisms such as the 
sea pansy that belong to the families Lampyridae and Renillidae respectively (103, 104).  
 
Figure 5: Schematic representation of a bioluminescent assay system driven by T7 
promoter and T7 polymerase 
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1.6.1 Minigenome construct 
Minigenomes are smaller in length and easier to manipulate. They usually only carry a 
single reporter gene open reading frame flanked by the leader and trailer as shown in figure 5 
(105). Thus, the minigenome system is constructed to mimic viral gene expression in the same 
way. 
 
     Promoters are found upstream of target genes for specific polymerases. The sequence of the 
promoter controls the binding of the RNA polymerase and transcription factors; therefore these 
regions determine where and when the gene of interest will be expressed (106). The leader and 
the trailer contain the gene start and the gene stop signals.  After transfection of the plasmid 
DNA into recipient cells, the plasmid DNAs are transcribed by the corresponding RNA 
polymerase to generate a negative-sense minigenome RNA, which is then encapsidated in the 
presence of the N. Next, with the help of P and L proteins, an encapsidated sense anti-
minigenome RNA is produced using the negative-sense encapsidated minigenomic RNA as a 
template. The positive strand is in turn used as template to generate the negative strand as a key 
step in viral replication. The encapsidated negative RNA strand is transcribed into messenger 
RNA (mRNA) lacking the complete 5- and 3- untranslated regions.  Finally, the transcribed 
mRNA is translated by host-cell machinery to produce the reporter proteins (84). 
 
      In a bioluminescent assay, cells are transfected with plasmids encoding for helper plasmids 
and the respective luciferase replicon reporter. Luciferase activities are determined 40 hours 
post-transfection using a luciferase substrate. Substrates are directly added to the cells and 
relative activities are quantified. The reporter protein's activity or fluorescence within a 
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transfected cell population is proportional to the steady-state mRNA level and thus gene 
expression. 
 
1.6.2 Transcription in the cytoplasm: T7 systems 
      T7 polymerase has been used for recovery of negative-sense RNA viruses. T7-system 
undergoes gene expression and requires entry in cytoplasm. There have been many advantages of 
T7-based system: various cell lines (such as Human embryonic kidney (HEK)-293T, Baby 
Hamster Kidney (BHK)-T7) can be used that provide exogenous T7 (37). Such permissive cell 
lines can be also used for virus recovery but the choice of cell lines in important based on viral 
cell tropism. Earlier, cytoplasmic T7 was provided by using recombinant vaccinia virus (78) but 
many of its cytopathic effects were found to hamper the T7-dependent system (79). Furthermore, 
transiently transfected (89) or stable transfection systems (103) have also been used to prevent 
such cytopathic effects.  
 
1.6.3 Transcription in the nucleus: pol I and pol II systems 
Three RNA polymerases are present in eukaryotes: 1) RNA polymerase (pol) I 
synthesizes the rRNA, without generating 5’caps and 3’tails. 2) pol II synthesizes mRNA and 3) 
pol III synthesizes tRNA. Eukaryotic RNA polymerases- pol I and pol III assists cellular 
transcription that accounts to 80% of total RNA synthesis. Transcription by pol 1 to synthesize 
rRNA is localized to discrete sites called nucleoli (107). 
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  Transcription of mRNA in mammalian cells via CMV promoter as a viral promoter or 
other eukaryotic promoters is dependent on cellular RNA polymerase II. Thus, expression of 
foreign genes by such vectors requires the entry of vectors into the nucleus (108).  
 
The pol I-based system has gained attraction over the T7- based system in the 
development of reporter assays for segmented RNA viruses like influenza. It was first developed 
as a solution to generate this complex recombinant virus as RNA pol-I assists nuclear 
transcription (109, 110). Pol-I system has many advantages such as: 1) does not require 
exogenous T7 polymerase 2) does not need ribozyme cleavage (106). 
 
1.7 Bicistronic and Tricistronic Reporter Assays 
      Multicistronic reporter assays can test the negotiation of intergenic junctions by the 
RdRp complex in negative sense non-segmented viral genomes. By using such multicistonic 
constructs for reporter based assays systems, we could determine if the transcription gradient is 
compromised in the subsequent genes. As monocistronic assay system does not consider the 
RdRP travel through the intergenic junctions, we were able to identify a system that could be 
used for testing the polymerase activity and the successful negotiation of intergenic junctions by 
the RdRp complex in negative sense non-segmented viral genomes. 
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Figure 6: Schematics of the bi- and tricistronic minigenome plasmids generated 
(firefly luciferase; nanoLuc, nanoluciferase; IGS- intergenic segment; Le- leader sequence; 
Tr, -trailer sequence; P_stopstop, MeV P protein–encoding ORF harboring a tandem stop 
codon after the 21st triplet) (100) 
 
Firtly, the MeV bicistronic replicon was first cloned  using monocistronic MeV replicon 
(111) as the template. Recombineering PCR technique was performed to generate a bicsistronic 
construct cassette that consists of one intergenic junction between two reporters. Secondly, the 
bicstronic construct was used as a backbone to generate a tricistronic construct. This construct 
had two intergenic junctions placed in between three ORF’s as shown in figure 6. 
 
Limitations: Despite the wide use of the reporter system, there are limitations to this approach. 
The viral infectious cycle environment is very different from the intracellular environment for 
the plasmid-based expression of helper plasmids. Many types of plasmids need to be transfected 
that can limit the efficiency of transfection and target gene expression and the ratio of plasmids 
need to be adjusted. Furthermore, a viral minigenome is shorter than its full-length genome. 
These limitations should be considered for designing a reporter assay system. 
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2  MATERIALS AND METHODS 
For additional methods, refer Appendix I: Thakkar V.D., Cox R.M., et al (2018): The 
Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain Modulates Viral Pathogenesis 
through Regulation of Transcriptase Activity. Journal of Virology. 
 
2.1   Cell Culture 
Human embryonic kidney (HEK293, CRL-3216; ATCC), Baby hamster kidney cells (C-
13; ATCC) stably expressing T7 polymerase (BSR-T7/5, (112)) and African green monkey 
kidney epithelial cells (CCK-81; ATCC) stably expressing human or canine signaling 
lymphocytic activation molecule (Vero-hSLAM and Vero-cSLAM, respectively (113)) were 
maintained at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with 
7.5% fetal bovine serum. All stable cell lines were incubated in the presence of G-418 (100 
µg/ml) at every fifth passage. GeneJuice (Novagen) reagent was used for all transient 
transfections of cells.  
 
2.2   Molecular biology 
Plasmids encoding expression constructs of MeV strain Edmonston N, P, and L (103), MeV 
strain IC-B N, P, and L (62, 80), CDV strain Onderstepoort N, P, and L (29), and NiV N, P, and 
L (114) were previously described. Likewise, plasmids harboring full length cDNA copies of the 
MeV strain IC-B genome (62), CDV strain 5804PeH genome (115), the different MeV 
minireplicons (100), and shuttle vectors harboring MeV strain IC-B and CDV strain 5804PeH 
derived N ORFs were previously reported (80). A cloning strategy developed in our earlier work 
(80) was applied to generate all MeV, CDV, or NiV-encoding N genes with internal Ntail 
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truncations. Briefly, sets of PCR primers were engineered that flanked the specific nucleotides 
targeted for deletion and contained terminal Afe-I restriction sites in frame with the N ORF. 
Religation of the Afe-I digested PCR products reconstituted the expression plasmid, now 
replacing the targeted Ntail section with Ser-Ala residues encoded by the Afe-I site. All Ntail 
modifications were confirmed by DNA sequencing. In addition, all full-length genome plasmids 
were sequence-confirmed prior to recovery transfection of recombinant virions. To generate a 
NiV nano luciferase minireplicon reporter construct, the Nano luciferase gene was amplified 
using appropriate PCR primers and the resulting product cloned into an existing NiV replicon 
backbone (114) that was likewise PCR amplified using appropriate primers. The nano-luciferase 
amplicon was ligated to the replicon vector backbone using the NeBuilder kit in accordance with 
the manufacturer’s protocols (New England Biolabs), and the resulting plasmid sequence 
verified. 
 
2.3   Immunoblotting 
BSR-T7/5 cells transfected in a 12-well plate format (4x105 per well) with 2 µg of MeV or 
CDV N-encoding expression plasmid DNA were washed once 40 hours after transfection with 
phosphate buffered saline (PBS) and lysed in RIPA buffer (1% sodium deoxycholate, 1% NP-40, 
150 mM NaCl, 50 mM Tris-Cl, pH 7.2, 10 mM EDTA, 50 mM NaF, 0.05% SDS, protease 
inhibitors [Roche]. Cleared lysates (20.000xg, 10 min, 4°C) were mixed with 5 x urea buffer 
(200 mM Tris, pH 6.8; 8 M urea; 5% sodium dodecyl sulfate (SDS); 0.1 mM EDTA; 0.03% 
bromphenol blue; 1.5% dithiothreitol). Samples were denatured for 30 min at 50°C, fractionated 
on 10 % SDS-PAGE gels, blotted on polyvinylidene difluoride (PVDF) membranes and 
subjected to enhanced chemiluminescence detection using specific antibodies directed against 
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MeV-N (MAB8905, Millipore), CDV (DV2-12, Bio-Rad), CDV-N-core (clone 1214) (116) and 
GAPDH (6C5, Ambion) as specified. Immunoblots were developed using a ChemiDoc digital 
imaging system (Bio-Rad), and the Image Lab software package (Bio-Rad) for image 
visualization. When applied, densitometry was carried out on non-saturated images with global 
background correction.  
 
2.4   Minireplicon luciferase reporter assay 
BSR-T7/5 cells (5,000 in a 96-well plate format) were transfected with plasmids encoding 
for IC-B-L (0.02 µg), IC-B-P (0.02 µg), IC-B-N (0.016 µg) and the respective MeV luciferase 
replicon reporter (0.044 µg). CDV minireplicon assay were performed accordingly using CDV 
helper plasmids. For NiV minireplicon experiments, cells were transfected with NiV-L (0.005 
µg), NiV-P (0.005 µg), NiV-N (0.01 µg), and NiV nanoluciferase replicon reporter (0.06 µg) 
encoding plasmid DNA. Firefly or nano luciferase activities were determined 40 hours post-
transfection in a Synergy H1 microplate reader (BioTek), using Bright-Glo or Nano-Glo 
luciferase substrate (Promega), respectively. Substrates were directly added to the cells and 
bioluminescence quantified after a 3-minute incubation for signal stabilization. Relative RdRp 
activities (relA) were determined on the basis of the formula % relA = (experimental − 
signalmin)/(signalmax − signalmin) × 100, with signalmax corresponding to cells transfected with 
plasmids encoding the standard NiV proteins and signalmin representing cells that received equal 
amounts of empty vector (pUC-19) in place of the N-encoding plasmid. All experiments were 
performed in at least 3 independent replicates, each measured in nine dependent repeats.  
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2.5   Virus recovery  
Recombinant MeV or CDV were recovered in BSR-T7/5 cells by transfecting 1.25 µg of the 
cDNA copy of the modified genome and IC-B-N (0.42 µg), IC-B-P (0.54 µg) and IC-B-L (0.55 
µg). All recombinant CDV genomes harbored an additional transcription unit encoding the 
mKate fluorescent protein in pre-L ORF position, which does not affect viral pathogenicity 
(115). Transfected cells were overlaid 48 hours after transfection onto Vero-hSLAM or Vero-
cSLAM cells and emerging infectious particles were passaged in Vero-hSLAM or Vero-cSLAM 
cells, respectively. Integrity of newly rescued virus strains was confirmed by extracting total 
RNA from infected cells (RNeasy mini kit, Quiagen) and generating cDNA copies using random 
hexamer primers and Superscript III reverse transcriptase (Invitrogen). Modified genome regions 
were amplified using appropriate primers and subjected to Sanger sequencing. 
 
2.6   Preparation of virus stocks  
MeV and CDV virus stocks were prepared by infecting Vero-hSLAM or Vero-cSLAM cells 
at a multiplicity of infection (MOI) of 0.01 50% tissue culture infectious dose (TCID50) units per 
cell, followed by incubation at 37°C. When microscopically observed virus-induced 
cytopathicity reached approximately 90%, cell-associated progeny particles were released 
through freeze/thaw cycles and titers determined by TCID50 titration on Vero-hSLAM or Vero-
cSLAM cells as described (117).  
 
2.7   Multi step virus growth curves 
Prior to infection for multi-step growth curves, viral stocks were diluted to approximately 
1x104 TCID50 units/ml and exact titers determined in a separate aliquot by TCID50 titration. 
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Vero-hSLAM or Vero-cSLAM cells (1×105 per well in a 12 well format) were infected with the 
different MeV or CDV strains at a MOI of 0.01 TCID50 units per cell for 1 hour and the 
inoculum replaced with DMEM growth medium. Individual wells were harvested in 12-hour 
intervals and cell-associated progeny virus titers determined by TCID50 titration. At least three 
independent growth curves were generated for each virus strain examined. Virus-induced 
cytopathicity in infected cells was documented using an inverted fluorescence microscope 
(Nikon) equipped with digital imaging package.  
 
3 RESULTS 
3.1  RSV minireplicon under pol1 control 
 (Refer Appendix III: Yan, D., Lee, S., Thakkar,V.D., Luo, M., Moore, M. L., & Plemper, R. K. 
(2014): Cross-resistance mechanism of respiratory syncytial virus against structurally diverse 
entry inhibitors. PNAS) (118). 
 
       Various luciferase reporters are used for a high-throughput screening (HTS) protocol design 
that can identify paramyxovirus-speciﬁc, orthomyxovirus-speciﬁc, or broadly specific 
compounds in a single assay system (101). The goal was to develop pol-I reporter system for use 
in RSV nucleoside analog testing. 
 
As discussed earlier, pol-I system has many advantages such as: 1) the pol I enzyme is 
expressed in the nucleolus of all eukaryotic cells and therefore does not need to be provided 
in trans. 2) transcripts generated by the pol I constructs have precise viral ends, i.e., they lack the 
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5′ cap structure and the 3′ poly A tail (119, 120).  3) the pol I system does not have the potential 
inherent disadvantage of vaccinia virus cytopathocity (119, 120).   
 
Experimental Results: Firstly, TOPO-cloning was performed using the RSV primers to 
generate RSV leader-Firefly-trailor casette. 
 RSV forward 5’-CGTCTCCTATTACGAGAAAAAAAAGTGTCAAAAAC-3’  
 RSV reverse 5’-CGTCTCGGGGGACGGGAAAAAATGCGTACAAC-3’  
 
The resulting product was cloned into an existing replicon by using BsmB-I restriction site. 
Based on a described pT7-RSV-luciferase minigenome reporter (121), this RSV minigenome 
construct (pHH-RSV-repl-firefly) was generated under the control of the constitutive RNA pol I 
promoter (as shown in the figure 7). This construct was then tested using varied amounts (0.8-
2.5ug) for reporter activity in order to test the amount of reporter to be used subsequently. To 
determine the relative luciferase reporter activities, Human embryonic kidney (HEK293/293T) 
cells were used at 28 and 50h post-transfection because it has high pol-1 activity inherently. 
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Figure 7: Monocistronic pol-1 based RSV minigenome 
A.Schematics of the Pol-I minigenome RSV plasmids generated (firefly- firefly luciferase; Le, 
leader sequence; Tr, trailer sequence. 
B.Graphic map of the pol-I minigenome RSV plasmid generated 
 
RNA pol-I terminator:  
AAAAAAAAAAAAAAAAAAAAAAAAAAGAGTCCAGAGTGGCCCCGCCGTTCCGCGC
CGGGGGGGGGGGGGGGGGGGGACACTTTCGGACATCTGGTCGACCTCCAGCATCGG
GGGAAAAAAAAAAAACAAAGTTTCGCCCGGAGTACTGGTCGACCTCCGAAGTTGGG
GGGG 
Restriction map of PHH21 minireplicon Firefly .xdna  -  4570  nt   [using RELibrary as a Restriction Enzyme Library]
<Serial Cloner V2.5> -- <Mar 14, 2018   12:58 PM>
A 
B 
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3’ non-coding- Leader:  
agtagaaacaggGTAGATAATCACTCACTGAGTGACATC 
 
Firefly Luciferase- ORF:  
atggaagacgccaaaaacataaagaaaggcccggcgccattctatcctctagaggatggaaccgctggagagcaactgcata
aggctatgaagagatacgccctggttcctggaacaattgcttttacagatgcacatatcgaggtgaacatcacgtacgcggaatacttcgaaa
tgtccgttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcgtatgcagtgaaaactctcttcaattctttatg
ccggtgttgggcgcgttatttatcggagttgcagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagtatgaacatttcgc
agcctaccgtagtgtttgtttccaaaaaggggttgcaaaaaattttgaacgtgcaaaaaaaattaccaataatccagaaaattattatcatggatt
ctaaaacggattaccagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccggttttaatgaatacgattttgtaccagagtcctt
tgatcgtgacaaaacaattgcactgataatgaattcctctggatctactgggttacctaagggtgtggcccttccgcatagaactgcctgcgtc
agattctcgcatgccagagatcctatttttggcaatcaaatcattccggatactgcgattttaagtgttgttccattccatcacggttttggaatgttt
actacactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttttacgatcccttcaggattacaaaattca
aagtgcgttgctagtaccaaccctattttcattcttcgccaaaagcactctgattgacaaatacgatttatctaatttacacgaaattgcttctggg
ggcgcacctctttcgaaagaagtcggggaagcggttgcaaaacgcttccatcttccagggatacgacaaggatatgggctcactgagacta
catcagctattctgattacacccgagggggatgataaaccgggcgcggtcggtaaagttgttccattttttgaagcgaaggttgtggatctgg
ataccgggaaaacgctgggcgttaatcagagaggcgaattatgtgtcagaggacctatgattatgtccggttatgtaaacaatccggaagcg
accaacgccttgattgacaaggatggatggctacattctggagacatagcttactgggacgaagacgaacacttcttcatagttgaccgcttg
aagtctttaattaaatacaaaggatatcaggtggcccccgctgaattggaatcgatattgttacaacaccccaacatcttcgacgcgggcgtg
gcaggtcttcccgacgatgacgccggtgaacttcccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtg
gattacgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacgaagtaccgaaaggtcttaccggaaaac
tcgacgcaagaaaaatcagagagatcctcataaaggccaagaagggcggaaagtccaaattgtaa 
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5’ non-coding- Trailer:  
AGAAAAATACccttgcttctact 
 
RNA pol-I promoter:  
aataACCCGGCGGCCCAAA 
 
HEK293/293T cells were cotransfected with 0.8ug, 1.5ug, 2ug or 2.5ug pol-I reporter with 
optimized ratios of RSV helper plasmids (N, P, M2 (0.4ug/well each) and L (0.2ug/well)) under 
CMV promoter control (122). Luciferase reporter activities were determined at 28 and 50 h after 
transfection activity in order to test the amount of reporter to be used subsequently. 
 
Figure 8: Minireplicon analysis of a firefly luciferase-RSV reporter in 293T cell line 
at 28 and 50h post-transfection.  
Activity represents relative luciferase reporter activities. Values represent averages of two 
dependent experiment, determined as ± SD. 
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The pol-I reporter was reported to be active with 2ug at 50 hours post transfection as shown in 
the figure 8. This experiment showed technical errors as the reporter showed increasing activity 
with increasing amounts of reporter for 28 hours post transfection. This was not observed for 50 
hours post infection activity profile. But this reporter was active and was used further in RSV 
reporter assays in nucleoside analog testing. 
 
3.2 Polycistronic minireplicons 
(Refer Appendix II: Cox, R. M., Krumm, S. A., Thakkar,V.D., Sohn, M., & Plemper, R. K. 
(2017): The structurally disordered paramyxovirus nucleocapsid protein tail domain is a 
regulator of the mRNA transcription gradient. Science Advances) 
 
     The natural paramyxovirus transcription gradient of mRNA synthesis has been shown to 
affect by the structurally disordered central Ntail section through two synergistic effects- 1) 
promoting the initiation of the transcriptase complex and 2) reducing the success of the 
transcriptase to negotiate the entire genome (123). To address whether N-tail mutants allow 
RdRp to efficiently negotiate the intergenic junctions in the viral genome, a process that involves 
the nontemplated polyadenylation of the newly synthesized mRNA, migration of the RdRp 
complex to the next downstream transcription start sequence, and reinitiation of RNA synthesis, 
we generated a novel firefly luciferase and nanoluciferase bi- and tricistronic minigenome 
reporter plasmids.  
 
     Pseudotemplated addition of nucleotides or RNA editing, as described earlier, occurs in P. 
The P reading frame was chosen because of its RNA editing site, which makes the RdRp stutter 
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and may enhance the likelihood for premature termination of replication in order to evaluate the 
successful negotiation of intergenic junctions and to determine the polymerase activity of 
different MeV N-tail mutants in Morbilliviruses with the help of multicistronic minireplicons 
since the monocistronic minireplicons cannot address this question. 
 
      The bicistronic reporter harbors the N/P open reading frame (ORF) intergenic junction of the 
MeV genome between the luciferase reporter genes, whereas the tricistronic plasmids contains 
the entire MeV P ORF including the N/P and P/M intergenic junctions. Firstly, the MeV 
bicistronic replicon was cloned using monocistronic MeV replicon (111) as the template. 
Recombineering PCR technique was used with the help of Aat II and Avr II sites to create a 
firefly luciferase–(P/M-IGS)–gaussi cassette. But, this bicistronic construct did not show any 
appreciable activity for the Gaussi luciferase reporter and the construct was then exchanged for 
the nanoluciferase reporter construct. By cloning with the help of Pac I and Avr II sites, this 
bicistronic cassette was introduced it into an existing monocistronic MeV minigenome (111). 
 
      The bicistronic construct served as the backbone for the tricistronic variant. Again by 
recombineering PCR, a second intergenic junction cassette was cloned into the former with the 
help of Pac I and Aat II sites. An eGFP protein (with the same intergenic junctions as the others 
N-P and P-M), Pstopstop or P_ORF_without the editing site-(1200bp shorter) P-(ΔCV) was 
placed as the 2nd ORF in between two intergenic junctions.  In the case of Pstopstop, a tandem 
stop codon was introduced into the ORF to avoid influencing minireplicon activity through 
additional P protein originating from the tricistronic minigenome, The stop codon was inserted 
21 triplets downstream of the start codon.  
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 Figure 9: Bi- and Tricistronic minigenome assays -quantitating negotiation of intergenic 
junctions in the presence of transiently expressed MeV N standard and mutant plasmid 
MeV NΔ439-482. 
(contributed by K.Wabbel and R.K.P- from Institute for Biomedical Sciences, Georgia State 
University) 
A) Minireplicon analysis of the MeV N mutant using a Bicistronic minigenome reporter. 
Activity represents normalized (to the mutant) ratio – second ORF (nano luciferase) versus first 
ORF (firefly luciferase) reporter activities of each biological replicate. Values represent averages 
of at least three independent experiments, determined in nonuplets each ± SEM. Shown is a 
comparison of two out of three data sets generated. Experimental variation was assessed through 
one-way analysis of variance (ANOVA) combined with Tukey’s multiple comparison post test 
(*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant). B) Schematic of the tricistronic 
minigenome plasmids generated (firefly, firefly luciferase; nanoLuc, nanoluciferase; IGS, 
intergenic segment; Le, leader sequence; Tr, trailer sequence; eGFP, P_stopstop and P-ORF – 
without the non-structural proteins C and V – P-(ΔCV) – 2nd ORF.  C) Minireplicon analysis of 
the MeV N mutant using a Tri-cistronic minigenome reporter. Activity represents normalized (to 
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the mutant) ratio- third ORF (nano luciferase) versus first ORF (firefly luciferase) reporter 
activities of each biological replicate. Values represent averages of at least three independent 
experiments, determined in nonuplets each ± SEM. Experimental variation was assessed through 
one-way analysis of variance (ANOVA) combined with Tukey’s multiple comparison post-test 
(*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant). 
 
      Bi- and Tricistronic minigenome reporter assay measures the negotiation of intergenic 
junctions in the presence of the MeV-N mutant was first tested as above (figure 9). In this 
protocol, BHK-T7 cells were cotransfected with either reporter and helper plasmids under T7 
promoter control. For analysis of the minigenome data, data sets obtained for each reporter were 
normalized in the presence of the mutant N. Later, the ratios of normalized nanoluciferase versus 
firefly luciferase signals for standard N was calculated. In the presence of the different 
constructs, this kind of approach enables us to appreciate the relative efficiency with which the 
RdRp complex accesses the downstream relative to the upstream reporter. 
 
In case of bicistronic construct, the relative reporter expression levels of MeV N-(Δ439-
482) were higher than standard N. In the case of tricistronic P-stopstop construct, the relative 
reporter expression levels did not differ significantly. For viral foreign proteins like eGFP and a 
highly truncated P that lacks the reading frames for C and V – (P-(ΔCV), significantly lower 
transcription efficiency in the presence of the N mutant was observed. Whether this finding is 
due to the shortened reading frames (both tricistronic constructs are shorter than the original P 
ORF) or due to RdRp processivity is further needed to be determined. It was demonstrated that 
through minireplicon assays that the mutant N did not affect RNA editing in the P open reading 
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frame. These results show that the non-structural proteins C and V do not influence the 
multicistronic RdRp activity and also shows successful negotiation of intergenic junctions by the 
RdRp complex in the absence of the unstructured morbilliviral Ntail section.  
 
3.3 Paramyxovirus Nucleocapsid Protein Tail Domain Modulation 
The functional importance of the structurally disordered central Ntail sections for paramyxovirus 
polymerase activity is currently mechanistically poorly understood, although it was thought that 
it provides structural flexibility to MoRE for recruitment of the polymerase complex (124, 125).  
 
Figure 10:  Schematic of the morbillivirus Ntail organization  
(model by R. M Cox - from Institute for Biomedical Sciences, Georgia State University) 
 A) Model of the full-length measles N protein. The Ntail domain (134 amino acids) missing 
from the cryoEM reconstruction of Ncore (blue-grey; PDB 4UFT) was added using Coot for 
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relative length illustration only. Conserved box regions are highlighted in yellow, orange, and 
green according to their position in the linear sequence. Heat maps (red) represented the 
predicted degree of structural disorder. Cartoon representations of the assembled MeV 
nucleocapsid assume a perpendicular orientation of Ntail to the axis of the helical RNP assembly 
(right). Ntail originates at the inner surface of the RNP and box1 residues are predicted to be 
buried between the rungs of the helix. B, C) Models of Ntail mutants after partial (B) or nearly 
complete (C) removal of the disordered central Ntail section. The truncations posit box2 and 3 
regions in close proximity to the trunk of the RNP assembly. D) Sequence alignment of the MeV 
and CDV Ntail domains. Box1-3 domains are color-coded as described in (A). Truncation donor 
(red) and acceptor (green) residues explored in this study are highlighted. Alignments were 
generated using T-Coffee [69] and structural models of MeV Ntail variants created in Pymol 
[70]. 
 
To test whether the morbillivirus unstructured central Ntail section is required for virus 
replication, we first designed a series of progressively larger internal tail deletions in MeV N, 
commencing with the removal of residues between positions 439 and 482, located just upstream 
of the conserved MoRE and box3 and extending to elimination of most of the structurally 
disordered residues between box1 and MoRE (figures 10A-C). Figure 10D provides an overview 
of all morbillivirus (MeV and CDV) Ntail truncations targeted. The largest deletion in MeV N 
eliminated all of Ntail between residues 399 and 482, which also includes the conserved box1 
region at the N-terminal origin of the tail. Naturally, gradual removal of the central Ntail residues 
will position the C-terminal end of Ntail harboring MoRE and box3 in immediate proximity of 
the trunk of the helical RNP assembly, ultimately predicting the placement of MoRE 
 36 
immediately proximal to the interface between consecutive turns of the RNP helix. 
 
Figure 11: Bioactivity of MeV and CDV N protein mutants with different length deletions 
in the disordered central tail section. 
 A, C) Steady state levels of MeV (A) and CDV N (C) protein mutants in cells BHK-T7 cells 
transfected with N protein-encoding plasmid DNA. Immunoblots were decorated with specific 
antibodies directed against MeV and CDV N protein, respectively, or cellular GAPDH for 
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sample processing control. Numbers represent means of densitometry quantitations of three 
biological repeats ± SEM; all uncropped blots are shown in supplementary figures 5 and 6.  B, 
D) Monocistronic minigenome assays testing bioactivity of the N protein mutants specified in 
(A) and (C). Symbols represent relative luciferase units of each biological replicate, determined 
each in nine technical replicates and normalized for values measured for standard N protein. 
Columns show sample means ± SEM; P values are based on one-way ANOVA with Tukey’s 
multiple comparison post hoc test, F: 18.1 (B) and 37 (D).  E, F) Tricistronic minigenome assays 
-quantitating negotiation of intergenic junctions in the presence of the N protein mutants 
(contributed by K.Wabbel, J. Sourimant and R.K.P- from Institute for Biomedical Sciences, 
Georgia State University). Symbols represent third ORF (nano luciferase) versus first ORF 
(firefly luciferase) reporter activities of each biological replicate, each measured in nine technical 
replicates. Columns show samples means ± SEM; P values are based on one-way ANOVA with 
Tukey’s multiple comparison post hoc test, F: 30.6 (E) and 4.8 (F); NS: not significant). 
 
Western blot analyses of cell lysates after transient transfection with plasmids encoding these 
mutants confirmed stable expression of all modified N proteins and revealed a gradual increase 
in electrophoretic mobility with expanding truncation size as anticipated (figure 11A). The two 
constructs harboring partial or complete deletions of box1 (NΔ399-482 and NΔ409-482), 
resulted in substantially reduced or no appreciable minireplicon activity, respectively.  All other 
mutants supported efficient RdRp activity in a monocistronic minireplicon reporter assay (figure 
11B). While average relative RdRp activities varied slightly compared to those observed in the 
presence of standard MeV N, none of these changes was statistically significant.  
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Encouraged by these results, we generated a comparable series of CDV N deletion mutants 
informed by the Ntail linear sequence alignments as outlined (figure 10D). Resembling the 
corresponding MeV N mutants, expression levels and bioactivity of CDV NΔ441-479 and 
NΔ425-479 was indistinguishable from that of standard CDV N in Western blotting and 
minireplicon assays (figures 11C and D). However, larger truncations (CDV NΔ423-479 and 
NΔ421-479, respectively) resulted in significantly enhanced minireplicon activities. As noted for 
MeV, truncation encroaching into the box1 section abolished CDV N bioactivity.  
 
Since monocistronic minireplicons cannot address whether the viral transcriptase retains the 
ability to successfully negotiate intergenic junctions, we employed a tricistronic minireplicon 
construct that contains two intergenic junctions and distinct firefly and nano luciferase reporter 
genes in the first and third reading frame position, respectively. In this assay, the relative ratio of 
downstream versus upstream reporter activity serves as an indicator for the efficiency with which 
the RdRp complex advances through intergenic junctions and reinitiates mRNA synthesis. When 
tested in the presence of a subset of the MeV (figure 11E) and CDV (figure 11F) Ntail mutants, 
only the MeV NΔ420-482 construct returned a slight (approximately 25%) but statistically 
significant relative reduction of third ORF expression. In the presence of all other constructs, 
relative reporter expression levels did not differ significantly from those observed with standard 
N, suggesting successful negotiation of intergenic junctions by the RdRp complex in the absence 
of the unstructured Ntail section.  
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Figure 12: Bioactivity of corresponding Henipavirus N protein mutants  
(performed in assistance with R. M Cox, Institute for Biomedical Sciences, Georgia State 
University) 
 A) Schematic of the NiV Ntail organization and disorder prediction, color-coded as in 
supplementary figure 1A. Ntail truncations eliminate the predicted helical box4 near the center of 
Ntail.  B) Sequence alignment of the MeV and NiV Ntail domains, color-coded as in (A). The 
individual truncation donor (red) and acceptor (green) sites are highlighted. Alignments were 
generated using T-Coffee.  C) Minigenome activity analysis of the NiV N protein mutants. 
Symbols represent individual biological replicates, each determined in nine technical replicates. 
Columns show sample means ± SEM; P values are based on one-way ANOVA with Tukey’s 
multiple comparison post hoc test, F: 19.1; df1: 2, df2: 6. 
 
To evaluate whether continued RdRp activity in the absence of the central Ntail section extends 
to paramyxoviruses outside the morbillivirus genus, we applied an equivalent truncation strategy 
to the Ntail of highly pathogenic NiV, a member of the recently established henipavirus genus 
(figures 12A and B). Although the organization of the NiV tail is predicted to be more complex 
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than that of the morbilliviruses, featuring an additional box4 in the central Ntail section (126), 
NiV RdRp also readily accepted template RNA encapsidated by tail-truncated N (figure 12C). 
Whereas a NiV NΔ424-471 mutant protein with large truncation showed standard NiV N-like 
activity in minireplicon assays, bioactivity of the NiV N construct harboring a shorter NΔ443-
471 truncation was also significantly increased.  
 
Figure 13: Recovery of recombinant MeV and CDV expressing N protein mutants. 
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A, B) Electrophoretic mobility profiles of N proteins expressed by the different recMeV (A) and 
recCDV (B) strains. Whole cell lysates of infected Vero-hSLAM and Vero-cSLAM cells, 
respectively, were subjected to immunoblotting and detection with specific antibodies directed 
against the MeV or CDV N protein. C, F) Multi-step growth curves of the different recMeV (C) 
and recCDV (F) strains recovered. Vero-hSLAM and Vero-cSLAM cells, respectively, were 
infected at an MOI of 0.01 TCID50 units/cell, followed by sampling and titration of cell-
associated progeny virus at the indicated time points. Values represent means of three 
independent experiments ± SEM. D, G) Regression modeling of growth profiles shown in (C) 
and (F). (contributed by R.K.P- from Institute for Biomedical Sciences, Georgia State 
University).  Bindslev’s population growth four-parameter variable slope model was applied 
(PDTmax, maximal population doubling time; Titermax, titer corresponding to the top plateau of 
the regression models; values in parentheses specify 95% confidence intervals; * denotes non-
overlapping confidence intervals relative to standard recMeV; NS, overlapping confidence 
intervals). E, H) Cytopathic effect associated with the different recMeV and recCDV strains 
(contributed by R.M Cox- from Institute for Biomedical Sciences, Georgia State University). 
Microphotographs of infected cells were taken at the specified times post-infection at a 
magnification of 200×.  
 
RdRp activity in minireplicon assays is a necessary albeit not sufficient function to support a full 
viral replication cycle. We also substituted the N protein encoding ORFs in cDNA genome 
copies of MeV and CDV strains that are based on pathogenic viral isolates, MeV-IC-B (62) and 
CDV-5804PeH (115), with two different Ntail truncations each, MeV NΔ439-482 and NΔ420-
482, and CDV NΔ441-479 and NΔ425-479, respectively. These specific truncations were 
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selected on the basis that in each case they represent the shortest and largest internal tail 
truncation that did not significantly alter N bioactivity in the original monocistronic minireplicon 
assay. The corresponding recombinant viruses were recovered readily after rescue transfection 
and overlay onto receptor-positive Vero-humanSLAM (Vero-hSLAM) and Vero-canineSLAM 
(Vero-cSLAM) cells, respectively. DNA sequencing after RT-PCR amplification of recovered 
virus genomes and Western blot analyses of infected cell lysates (figures 13A and B) confirmed 
the presence of the respective Ntail truncations in the recombinant viruses.  
 
Multiple step growth curves revealed a parent virus-like replication profile for recMeV-IC-B 
NΔ439-482 (figure 13C), whereas recMeV-IC-B NΔ420-482 with the larger Ntail truncation 
showed an initial 12-hour growth delay. Modeling of growth profiles confirmed that maximal 
population doubling times of recMeV-IC-B NΔ420-482 were significantly longer than those of 
standard recMeV-IC-B, but differences between recMeV-IC-B NΔ439-482 and the parent strain 
remained not significant (figure 13D). Microphotographs of the infected cell populations at 
different times after infection demonstrated that cytopathic effects corroborated the virus titer-
based growth profiles (figure 13E). Interestingly, the growth pattern of the MeV mutants was 
inversed in the case of the recombinant CDV virus strains (figure 13F). recCDV-5804PeH 
NΔ425-479 carrying the larger truncation showed significantly shorter maximal doubling times 
than recCDV-5804PeH NΔ441-479 (figure 13G). However, maximal growth rates of both 
mutant strains lagged behind that of the parental recCDV-5804PeH, although growth profile 
modeling did not reveal significant differences in peak progeny titers reached. Visual 
examination of viral cytopathicity again showed only small differences between the two mutant 
strains and the parental recCDV (figure 13H). 
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These data demonstrate that the unstructured central Ntail section is not associated with an 
essential RdRp function required for virus replication, establish distinct effects of different 
length truncations on viral fitness in cell culture, and indicate that the actual impact of internal 
Ntail truncations on virus growth is not necessarily directly proportional to the length of the 
deletion but must be individually determined. 
 
Figure 14: Pathogenesis of the recCDV mutants in the ferret model  
(contributed by B. Sawatsky, and V. Messling- from Veterinary Medicine Division, Paul-Ehrlich-
Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany and R. Budaszewski- 
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from Paul-Ehrlich-Institut and Federal University of Rio Grande do Sul, Porto Alegre, Brazil) 
 A) Cell-associated viremia titers after intranasal infection of animals with the different recCDV 
strains. Symbols represent TCID50 units in 106 isolated PBMCs for each biological replicate; 
lines connect sample means (recCDV NΔ425-479-infected animals n = 4; recCDV NΔ441-479-
infected animals n = 7; recCDV-5804PeH-infected animals n = 4); P values are based on two-
way ANOVA with Tukey’s multiple comparison post hoc test; F: 2.9; df1: 2, df2: 10.  B) 
Survival curves. Statistical significance of differences between the curves was assessed through 
Mantel-Cox test, predicted median survival is shown; df: 2.  C) Virulence index for standard and 
mutant recCDV-5804PeH strains. Each box represents one animal, clinical score index ranges 
from high (black), to intermediate (grey) and absent (white). D) Body weight changes in the 
infected animals. Weight is expressed as the percentage of the initial weight at the day of 
infection. Symbols represent individual biological replicates; lines connect sample means; P 
values are based on two-way ANOVA with Sidak’s multiple comparison post hoc test; F: 7.5; 
df1: 1, df2: 9.  E) Fever curves of infected animals. Symbols represent body temperature for each 
biological replicate; lines connect sample means; P values are based on two-way ANOVA with 
Sidak’s multiple comparison post hoc test; F: 38; df1: 1, df2: 189.  F) Lymphopenia assessment. 
Symbols represent mean leukocyte counts per cubic millimeter of blood for each biological 
replicate; lines connect sample means; P values are based on two-way ANOVA with Tukey’s 
multiple comparison post hoc test; F: 0.91; df1: 2, df2: 10.  G) Nonspecific PBMC proliferation 
capacity. Symbols represent mean rations of 5-bromo-2’ deoxyuridine (BrdU) incorporation 
relative to nonstimulated PBMCs for each biological replicate; lines connect sample means; P 
values are based on two-way ANOVA with Tukey’s multiple comparison post hoc test; F: 0.42; 
df1: 2, df2: 11. 
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To evaluate the importance of Ntail for viral pathogenesis, we capitalized on the lethal 
CDV/ferret model that recapitulates key features of human morbillivirus disease such as host 
invasion strategy, tissue tropism, and replication profile (127). Ferrets were infected intranasally 
with 2×105 TCID50 units of standard recCDV-5804PeH, recCDV-5804PeH NΔ441-479, or 
recCDV-5804PeH NΔ425-479, and clinical signs, PBMC-associated viremia titers, white blood 
cell counts, and lymphocyte proliferation response were monitored in regular intervals. 
Consistent with our previous experiences with the model (128), peak viremia titers were reached 
seven days post-infection, followed by a rapid decline in viral load in animals infected with 
either of the N mutant viruses (figure 14A). All animals infected with standard recCDV-
5804PeH succumbed to the disease by day 14. By contrast, the group that had received recCDV-
5804PeH NΔ441-479 and 75% of animals in the recCDV-5804PeH NΔ425-479 group survived 
the infection (figure 14B). In recovering animals, viremia fully subsided 21 (recCDV-5804PeH 
NΔ441-479) and 35 (recCDV-5804PeH NΔ425-479) days after infection, respectively.  
 
Animals infected with the parental virus experienced severe disease with extensive rash, 
substantial weight loss, and high fever (figures 14C-E). By comparison, disease progression was 
less aggressive in animals infected with the recCDV-5804PeH NΔ425-479 mutant virus and mild 
in animals of the recCDV-5804PeH NΔ441-479 group. Specifically, recCDV-5804PeH NΔ441-
479-infected ferrets showed a benign, more localized rash and only transiently lost a moderate 
(<10%) amount of body weight before making a full recovery by conclusion of the study (figure 
11D). Fever peaked in these animals two to three days earlier and at a lower level than in 
recCDV-5804PeH and recCDV-5804PeH NΔ425-479-infected animals, and resolved within the 
second week after infection (figure 14E). In contrast, recCDV-5804PeH NΔ425-479 infected 
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ferrets presented with a more prolonged weight loss and fever fully resolved only in the third 
week after infection.  
 
Acute lymphopenia and temporary lack of lymphocyte responsiveness to stimulation constitute a 
hallmark complication associated with morbillivirus infections (129). When assessing immune 
competence of animals infected with the different viruses, we noted significantly milder 
lymphopenia early after infection in the recCDV-5804PeH NΔ441-479 group compared to 
animals that had received standard recCDV-5804PeH or recCDV-5804PeH NΔ425-479 (figure 
14F). However, lymphocytes derived from animals of all groups showed a similar decline in 
proliferation responsiveness during the first two weeks after infection (figure 14G). Proliferation 
response improved in all surviving animals only at 35 days post-infection, although we noted a 
temporary rebound in recCDV-5804PeH NΔ441-479-infected ferrets at the 21-day time point.  
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Figure 15: Immune responses to recombinant Ntail deletion mutant viruses  
(contributed by B. Sawatsky, and V. von Messling- from Veterinary Medicine Division, Paul-
Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany and R. 
Budaszewski- from Paul-Ehrlich-Institut and Federal University of Rio Grande do Sul, Porto 
Alegre, Brazil) 
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 A) Relative levels of type I IFN and Mx-1 message present in PBMCs isolated at days three and 
seven after infection of animals with the different CDV recombinants. Symbols represent the 
relative fold-change in mRNA level normalized to uninfected naive controls (day 0) for each 
biological replicate. Horizontal lines and error bars represent mean values ± SEM; t-tests were 
used for pairwise comparisons; one-way ANOVA with Sidak’s multiple comparison post hoc 
test was applied to Mx-1 day 7 fold-change analysis; F: 1.96; df1: 8, df2: 27.  B) Neutralizing 
antibody responses in plasma samples. Antibody titers are shown as the reciprocal of the highest 
dilution in which CPE was observed. Symbols represent individual biological replicates, lines 
connect sample means. P values are based on two-way ANOVA with Sidak’s multiple 
comparison post hoc test; F: 4.1; df1: 1, df2: 6.  C) Intranasal challenge of surviving animals 
from figure 4 with 2 x 105 TCID50 units of standard recCDV-5804PeH. Survival curves of 
animals after rechallenge at day 49 post-infection. For comparison, CDV-naïve ferrets were 
challenged in parallel (n = 3: recCDV NΔ425-479; n = 4: recCDV NΔ441-479; n = 4: recCDV-
5804PeH).  D) Cell-associated viremia titers in rechallenged animals. Symbols represent 
TCID50 units in 106 isolated PBMCs for each biological replicate, lines connect sample means; 
P values are based on two-way ANOVA with Tukey’s multiple comparison post hoc test; F: 
1448; df1: 2, df2: 8.  E) Lymphopenia assessment in rechallenged animals. Symbols represent 
leukocyte counts per cubic millimeter of blood for each biological replicate, lines connect sample 
means; P values are based on two-way ANOVA with Tukey’s multiple comparison post hoc test; 
F: 60.4; df1: 2, df2: 8. 
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Animals infected with either mutant virus mounted comparable type I interferon responses, 
reaching approximately 10-fold induction levels in IFN-α, β and Mx-1 message, the latter 
representing one of the major interferon-stimulated genes in response to CDV infection (figure 
15A).  
 
In the same manner, anti-CDV -5804PeH antibody responses were robust in animals of either 
group, although interestingly neutralizing antibody titers induced by the more attenuated 
recCDV-5804PeH NΔ441-479 peaked slightly higher than those found in animals of the 
recCDV-5804PeH NΔ425-479 group (figure 15B). To determine whether antibody titers 
mounted by the surviving animals infected with the Ntail modified recombinants were 
protective, we re-challenged with a lethal dose of standard recCDV-5804PeH at 49 days after the 
original infection. All challenged animals survived (figure 15C) and none developed appreciable 
viremia (figure 15D), showed clinical signs, or experienced severe lymphopenia (figure 15E).  
 
These results highlight a role of the unstructured Ntail section in paramyxovirus pathogenesis. 
Gradual shortening of the tail induces different degrees of viral attenuation, although not with 
direct proportionality. Importantly, all surviving animals in the CDV/ferret model were 
completely protected against a lethal challenge with standard CDV, underscoring efficient 
immunization by the Ntail-modified recombinant strains. 
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Table 1: Sequence analysis of recCDV strains after passage in cell culture and through 
ferrets 
(contributed by N. Makhsous, A. Greninger- from Virology Division, Department of Laboratory 
Medicine, University of Washington, Seattle, WA and with M. Russ and J. Sourimant- from 
Institute for Biomedical Sciences, Georgia State University) 
 
To assess the genetic stability of the recCDV with Ntail truncations, we subjected viral RNA 
preparations to deep sequencing before and after 10-11 passages in cell culture, and determined 
N ORF consensus sequences in viral RNA extracted from PBMCs harvested from ferrets seven 
days after infection through Sanger sequencing (table 1). Neither standard recCDV-5804PeH nor 
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recCDV-5804PeH NΔ441-479 showed any changes in the N nor P ORF compared to the genome 
cDNA plasmids that were used for virus recovery. In contrast, recCDV-5804PeH NΔ425-479 
carried a glutamate to glutamine substitution at N residue 156 that was dominant in the viral 
population after four passages in cell culture, and acquired an alanine to aspartate exchange at N 
residue 410 that became increasingly fixed during cell culture passaging. All recCDV-5804PeH 
NΔ425-479 recovered from infected ferrets at the peak of viremia likewise contained both N 
substitutions.  
 
Comparison with N sequences representing a variety of different circulating CDV strains and 
isolates revealed that the N ORF is fully sequence conserved at position 156 and shows only 
more conservative changes than the aspartate substitution at residue 410 (figure 16). 
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Figure 16: Alignment of a diverse pool of CDV N sequences representing clinical 
viral isolates and laboratory-adapted strains.  
(analyses by R.K.P, Institute for Biomedical Sciences, Georgia State University) 
Shown are strain identifiers, database access codes, and the areas surrounding the two residues in 
the N protein (156 and 410, respectively) featured in table 1. Alignments were created using T-
Coffee and outputs rendered with ESPript 3.0. 
 
None of the mutants or standard recCDV harbored any coding mutations in the P and L 
ORFs, with the exception of a single recCDV-5804PeH NΔ441-479 passaging line that carried a 
leucine to proline substitution at L residue 2175 with approximately 50% allele frequency after 
15 passages in cell culture (table 1). Since none of the other recCDV-5804PeH NΔ441-479 lines 
analyzed in parallel showed allele variation at this position, this mutation most likely represents a 
stochastic event that became partially fixed in the genome.  
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Figure 17: Analysis of RNA populations present in cells infected with Ntail mutant viruses 
in comparison with the parental strain. 
(contributed by R. M Cox, Institute for Biomedical Sciences, Georgia State University) 
 A, B) MiSeq analysis of viral mRNA editing in the P ORF after infection of cells with recCDV 
NΔ441-479 (A), recMeV NΔ439-482 (B), or the corresponding parent virus strains. Values 
represent a minimum of 91,741 reads each and are expressed as mean percentage of the 
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differentially edited mRNAs relative to the total transcripts from the P ORF ± SEM. C) qRT-
PCR quantitation of relative CDV genome copy numbers in cells infected with the recCDV Ntail 
mutants compared to standard recCDV. First strand synthesis with specific primers directed at 
the viral genome UTR, followed by amplification of a section of the N ORF. D, E) qRT-PCR 
quantitation of relative CDV N mRNA (D) and L mRNA (E) copy numbers present in RNA 
preparations as in (C), compared preparations from cells infected with standard recCDV. First 
stand synthesis with oligo(dT) primers, followed by amplification of sections of the N and L 
ORF. F to H) qRT-PCR quantitations of RNA preparations as in (C) of the relative ratios of L 
versus N encoding mRNAs (F), and of intergenic sequence (IGS) N/P (G) and mKate/L (H) 
encoding polycistronic mRNAs versus mRNAs encoding the IGS-preceding ORF. First stand 
synthesis with oligo(dT) primers, followed by amplification of sections of the N, mKate, and L 
ORF, respectively, or across the specified IGS sections. In (C) to (H), symbols represent 
individual values of three biological repeats analyzed in two technical repeats each. Columns 
show mean values ± SEM. P values are based on one-way ANOVAs with Tukey’s multiple 
comparison post hoc test; F ratios and df values are shown for each graph. 
 
To further elucidate the mechanistic basis for the altered CDV pathogenesis profiles, we 
analyzed viral RNA populations synthesized in cells infected with the different recombinant 
virus strains. Co-transcriptional paramyxovirus mRNA editing results in the expression of two 
additional proteins, V and W, from the viral P ORF through the insertion of non-templated G 
residues at an editing site (130-133). Of these P ORF products, the CDV V protein serves as the 
major suppressor of the host-cell innate antiviral response. RNA editing is thought to result from 
backsliding of the RdRp complex on the RNP template (130, 134, 135), which requires structural 
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flexibility that could be mediated by the flexible central Ntail section. Since impaired V protein 
expression causes viral attenuation (136), we employed a MiSeq assay to quantify the relative 
ratios of P, V and W-encoding mRNAs in infected cells. recCDV-5804PeH NΔ441-479 and the 
corresponding recMeV-IC-B-NΔ439-482 were selected for this analysis based on the superior 
level of attenuation of this shorter CDV truncation mutant in the ferret model. Relative mRNA 
distributions were comparable between MeV and CDV, but we noted only minor changes when 
mutant and the corresponding parent viruses were compared (figures 17A and B).  
 
Our recent characterization of an MeV recombinant that expressed a mutant N with MoRE 
relocated into Ncore and partially truncated tail revealed a steepened viral mRNA transcription 
gradient in infected cells (100). However, this MeV recombinant was temperature-sensitive and 
unable to replicate under physiological conditions. Based on this finding, we hypothesized that 
attenuation of the recCDV Ntail mutants in the ferret model may alternatively result from 
deregulated viral transcriptase activity, although more subtle than that experienced with the 
MoRE-relocated MeV recombinant. Using an RT-qPCR-based approach, we quantified viral 
genome copies in infected cells, determined relative N-encoding and L-encoding mRNA levels 
in cells infected with the mutant versus parental virus strains, examined relative ratios of L 
protein to N protein-encoding mRNAs produced by each virus strain, and calculated the relative 
frequencies with which polycistronic viral mRNAs are synthesized by each recombinant during 
replication.  
 
Viral genome copy numbers of both mutant recCDV strains were reduced by approximately 19 
to 29% at the end of the replication cycle compared to standard recCDV (figure 17C). By 
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contrast, N protein-encoding mRNA levels of either mutant strain were increased approximately 
1.8-fold relative to standard recCDV (figure 17D). Interestingly, when we examined relative 
mRNA levels of the downstream-most positioned L protein ORF, we noted that this 1.8-fold 
increase was maintained in recCDV-5804PeH NΔ425-479 infected cells, but boosted to an 
approximately 3-fold relative excess in cells harboring recCDV-5804PeH NΔ441-479 (figure 
17E). Analyzing ratios of L protein-encoding versus N protein-encoding mRNAs synthesized by 
each virus strain revealed a significant increase in relative amounts of L protein-encoding 
mRNAs only in cells infected with recCDV-5804PeH NΔ441-479, while essentially identical 
ratios were obtained for standard recCDV and the less attenuated recCDV-5804peH NΔ425-479 
(figure 17F).  
 
The higher relative L mRNA level produced by recCDV-5804PeH NΔ441-479 could reflect a 
relative increase in bona fide L message due to a lowered premature termination ratio of the 
advancing polymerase complex or due to a higher proportion of non-productive polycistronic 
mRNAs. To differentiate between these alternatives, we evaluated the relative content of 
polycistronic message generated at the first (figure 17G) and last (figure 17H) intergenic 
sequence (IGS) present in the recCDV genomes. Depending on the individual IGS examined, 
replication of the standard recCDV-5804PeH and recCDV-5804P NΔ425-479 strains resulted in 
the synthesis of 2-10% polycistronic message relative to the total message synthesized for the 
preceding ORF. At either IGS, however, we noted a significantly higher ratio of polycistronic 
message present in cells infected with the recCDV-5804PeH NΔ441-479 mutant strain. 
Sequence analysis of the polycistronic message after RT-PCR amplification of an N/P message 
fragment harboring the IGS revealed straight read-throughs of the transcriptase complex, lacking 
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any non-templated residues at the poly-adenylation site. These results implicate the structurally 
disordered central Ntail section in affecting paramyxovirus transcriptase function on two 
different levels. Both Ntail mutant strains show heightened transcriptase activity relative to the 
parental recCDV strain. In addition, the more severely attenuated recCDV-5804peH NΔ441-479 
further disturbs the relative ratio of viral message in infected cells by generating a higher 
proportion of non-productive polycistronic mRNAs.  
 
Figure 18: Predicted location of candidate compensatory mutation to the ND425-479 
truncation in a model of the CDV RNP assembly. 
(model by R. M Cox, Institute for Biomedical Sciences, Georgia State University) 
A) The E156Q mutation (red spheres) in Ncore is located near the position at which Ntails 
(yellow circles) are postulated to protrude from the RNP assembly. The homology model of the 
CDV nucleocapsid was created using the SWISS-Model homology-modeling server based on the 
structure of the MeV Ncore assembly (PDB ID: 4UFT). B) Side-view of consecutive rungs of the 
helical CDV RNP assembly. No structural information is available for the position of Ntail, but 
box1 residues (yellow squares) are predicted to locate close to the outer surface of the RNP or 
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between consecutive turns of the RNP helix (shown in the model). The position of the A410D 
substitution near the center of box1 is highlighted (red square). 
 
The observations demonstrate that the NΔ441-479 truncation is genetically stable over a 
number of generations in cell culture and after in vivo passage of the recombinant strain. 
Efficient growth of recCDV-5804PeH NΔ425-479 appears to be linked to the presence of two 
compensatory mutations, one located in Ncore (residue 156) and the second in box1 of Ntail 
(residue 410). Localization of CDV N residue 156 in a structural model of the morbillivirus RNP 
assembly posits this substitution at the C-terminal end of a flexible loop in Ncore (100), 
orientated towards the interface between consecutive turns of the RNP helix (figure 18) and in 
proximity to the site where Ntail is thought to emerge from the RNP core (88).   
 
Supplemental Results 
 
 We wanted to determine the virus recovery of N-(Δ439-482) mutant virus in the MeV-
Edmonston (Edm) vaccine strain. MeV-Edm vaccine strain has been extensively used in our 
laboratory. The truncations have been transferred to the MeV clinical isolate IC-B strain as 
shown in the Appendix 1 – Thakkar et al (2018). The hypothesis was that the kinetics of Edm 
mutant viruses would be different from the clinical isolate IC-B mutant viruses with the same 
truncation. 
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Figure 19: Recovery and expression analysis of recombinant Edmonston-MeV expressing N 
mutant. 
A-D) Multi-step growth curves of recMeV N(Δ439-482) cell-associated (A) or supernatant (B) 
virus recovered at 37°C respectively, and recMeV N(Δ439-482) cell-associated (C) or 
supernatant (D) virus recovered at 32°C respectively, as compared to the standard. Vero-hSLAM 
cells were infected at an MOI of 0.01 TCID50 units/cell, followed by sampling and titration of 
cell-associated/supernatent progeny virus at the indicated time points. Values represent means of 
at least three independent experiments ± SEM. E, F) Expression levels of growth-curve cell 
lysates of cell-associated virus strains recovered at 37°C (E) and at 32°C (F). Whole cell lysates 
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of infected Vero-hSLAM were subjected to immunoblotting and detection with specific 
antibodies directed against the MeV N protein.  
 
To determine the importance of the unstructured Ntail section in virus replication in the 
Edmonston strain, we substituted the N protein encoding ORFs in cDNA genome copies of 
MeV-Edmonston vaccine strain with MeV NΔ439-482. As discussed earlier, RdRp activity in 
minireplicon assays is not a necessary function to support viral replication cycle of that specific 
mutant. Surprisingly, the corresponding recombinant mutant virus was recovered readily after 
rescue transfection and overlay onto receptor-positive Vero-humanSLAM (Vero-hSLAM). DNA 
sequencing after RT-PCR amplification of recovered virus genomes confirmed these viruses. 
Multiple step growth curves were performed at 37°C and at 32°C (figure 19) with non-GFP 
containing viruses.  
 
     These results demonstrate that the growth-kinetics at 37°C revealed an initial 12-hour growth 
delay replication profile for recMeV-Edm- NΔ439-482 for the cell-associated and supernatant 
recombinant viruses as compared with its standard. On the other hand, the peak titers for 
recMeV-Edm- NΔ439-482 showed a 2-day delay profile at 32°C with respect to the cell-
associated and supernatant viruses. This was replicated in the whole cell lysates of these viruses. 
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Figure 20:  Recovery of recombinant Edmonston-MeV (GFP) expressing N mutants. 
A-C) Multi-step growth curves of recMeV-GFP N(Δ427-482) and recMeV-GFP N(Δ420-482) 
cell-associated viruses recovered at 37°C (A), at 32°C (B) or at 39.5°C (C). Vero-hSLAM were 
infected at an MOI of 0.01 TCID50 units/cell, followed by sampling and titration of cell-
associated progeny virus at the indicated time points. Values represent means of at least three 
independent experiments ± SEM. 
 
Secondly, we substituted the N protein encoding ORFs in c-DNA genome copies of MeV-Edm 
strain with MeV-GFP NΔ427-482 and with MeV-GFP NΔ420-482 respectively. MV 
recombinants expressing the green fluorescent protein (GFP) have been used to monitor the 
kinetics of the virus in the cell.  We have therefore placed the GFP-ORF in the first ORF before 
the N-protein ORF in order to observe them over a period of time. The corresponding 
recombinant mutant viruses were recovered readily after rescue transfection and overlay onto 
receptor-positive Vero-humanSLAM (Vero-hSLAM). DNA sequencing after RT-PCR 
amplification of recovered virus genomes. Multiple step growth curves were performed at 37°C, 
32°C and at 39.5°C (figure 20) with GFP containing viruses. 
 
A B C 
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These results demonstrate that the peak titers at 37° showed a 2 and 1.5-days delay 
profile respectively, with respect to the standard C for recMeV-Edm-GFP NΔ427-482 and 
recMeV-Edm-GFP NΔ420-482 respectively. The growth-kinetics of recMeV-Edm-GFP NΔ427-
482 and recMeV-Edm-GFP NΔ420-482 at 32°C showed a day-delay profile with half a log less 
titer for the former than the latter. Additionally, at 39.5°C, recMeV-Edm-GFP NΔ427-482 
mutant virus showed temperature-sensitivity, while recMeV-Edm-GFP NΔ420-482 mutant virus 
peaked its titers a day later as compared to its corresponding standard.  
 
This proves that the MeV replication is tolerant towards changes in both central Ntail 
sequence and its length but there is more pronounced effect in the Edmonston strain than in the 
clinical isolate IC-B strain. This also may be due to varying degrees of susceptibility of infection, 
relative innate immune responses or also as discussed earlier difference in usage of receptors in 
both the strains (the IC-B strain uses SLAM as a receptor, whereas the Edmonston strain can use 
both SLAM and CD46 as receptors). Although, there is no correlation between the intrinsically 
disordered central N-tail truncation and its specific viral fitness; further experiments are needed 
to test these mutants in vivo, specifically in rhesus or cynomolgus macaques. 
 
4 CONTINUED STUDIES 
     In order to probe the functional and mechanistic role of the central section of CDV-Ntail, we 
have many questions that have still remain unanswered such as: 1) can we truncate further down 
in the central CDV-N-tail section? 2) Can we truncate the CDV-N-tail section without an 
artificial Afe-I site? 3) Is there a motif in the central section of the CDV-N-tail? If yes, is the 
motif really important for viral replication? 4) Are the serine residues in the central section of 
 63 
CDV-N-tail phosphorylated? And are these residues important for virus rescue? Therefore, in 
order to evaluate the functional role of the central section of the CDV N-tail further we continued 
additional studies on the central section of the CDV N-tail. 
 
Because of the minigenome data of CDV NΔ423 and CDV NΔ421 in the previous study, 
we substituted the N protein encoding ORFs in cDNA genome copies of CDV strain CDV-
5804PeH. We also removed the artificial Afe-1 site and substituted the CDV NΔ425-479 
plasmid mutant with alanine and aspartic acid residues to create: CDVNΔ425-SERS, 
CDVNΔ425-SERA, CDVNΔ425-AERS, CDVNΔ425-AERA, CDVNΔ425-SERD, CDVNΔ425-
DERS, CDVNΔ425-DERD, respectively. The corresponding recombinant viruses were 
recovered readily after rescue transfection and overlay onto receptor-positive Vero-canineSLAM 
(Vero-cSLAM) cells. DNA sequencing after RT-PCR amplification of recovered virus genomes 
confirmed CDV NΔ425-SERA and CDV NΔ425-DERD mutants but showed a mutation in box 1 
of CDV NΔ425-SERS mutant recombinant virus (as shown in Table 2). This led us to believe 
that the Afe-1 restriction site (SA) replaces the hypothesized natural phosphorylation site in the 
central section of CDV-N-tail. 
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Table 2: Summary of recCDV N mutant viruses 
 
When we substituted N protein encoding ORF in cDNA genome copies of CDV strain 
CDV-5804PeH (wild type (wt)), with the CDV N_AERA (CDV5804-N422-425Ala) and CDV 
NΔ425-AERA, we could recover the former recombinant virus readily, but not the latter, after 
rescue transfection and overlay onto receptor-positive Vero-canineSLAM (Vero-cSLAM) cells. 
Finally, Vero-cSLAM cells were infected with CDV-5804PeH and CDV N_AERA at an MOI of 
0.01 TCID50 units/cell, followed by sampling and titration of cell-associated progeny virus at the 
indicated time points. The growth profiles overlapped as expected. 
 
In the case of CDV N_AERA, we believe that the downstream serine residues would be 
functional to regulate the phosphorylation activity we hypothesize in the central section of the 
CDV N-tail. And in the case of CDV NΔ425-AERA, the hypothesized phosphorylation site is 
important for CDV replication.  
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5 DISCUSSION 
      Bioluminescent assays are very commonly used to study gene expression as well as other 
cellular components and events that are involved in gene regulation. These assays are very 
sensitive–allowing quantification of even small changes in transcription– and the availability of 
results within minutes makes it appealing. They are extremely simple to use and relatively 
inexpensive. 
 
      In bacteria, there is only one enzyme, however, eukaryotes have many polymerases that are 
each responsible for a specific subset of RNAs. Various promoters are selected depending upon 
whether viral transcription occurs in the nucleus or the cytoplasm during replication of the virus. 
Although the majority of the RNA viruses replicate in the cytoplasm, the plasmids of this 
protocol undergo nuclear transcription and the transcripts then undergo the downstream 
processes in the cytoplasm. When human cells were cotransfected with different amounts of pol-
I reporter plasmid and with optimized ratios of RSV helper plasmids (N, P, M2 – (0.4ug/well 
each) and L (0.2ug/well). This was done in order to test the amount of reporter to be used 
subsequently. The reporter was found to be active but the amount of reporter activity was not 
directly proportional to the amount of reporter plasmid used at 50 hours post transfection as seen 
in 28 hours post transfection. Although, the pol-I reporter assay showed some technical errors 
and as the data was based on dependent replicates, the reporter was subsequently used in RSV 
nucleoside analog testing successfully. 
 
       Since monocistronic minireplicons cannot address whether the viral transcriptase retains the 
ability to successfully negotiate intergenic junctions, we employed a multicistronic reporter assay 
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system. We first generated a novel firefly luciferase and gaussiluciferase containing bicistronic 
minigenome constructs plasmids to address whether N-tail mutants allow RdRp to efficiently 
negotiate the intergenic junctions in the viral genome. This kind of minigenome construct did not 
show any appreciable signal and therefore we then generated firefly and nanoluciferase 
containing bi- and tricistronic minigenome reporter.  
 
      In case of the bi and varied tricistronic constructs, the relative reporter expression levels of 
MeV N-(Δ439-482) did not differ significantly as compared to the standard. In fact, the 
bicistronic assay showed higher RdRp activity with the mutant as compared to the standard. In 
the case of tri-P-stopstop construct, the relative reporter expression levels did not differ 
significantly but was shown to be lower in case of mutant with respect to tri-eGFP and tri-(P-
(ΔCV). Since both- tri-eGFP and tri-(P-(ΔCV) are shorter than tri-P-stopstop, it seems to be 
possible that the RdRp processivity depended on the extra residues missing. These results also 
led us to believe that the non-structural proteins C and V do not influence the multicistronic 
RdRp activity and show successful negotiation of intergenic junctions by the RdRp complex in 
the absence of the unstructured Ntail section. Additionally, we have also employed such a 
multicistronic (both bi- and tricistronic) reporter based system to determine RdRp activity in 
different morbilliviral N-tail truncated constructs with increasingly large internal truncations of 
central residues. 
 
We have also generated a series of MeV, CDV, and NiV mutant N proteins with 
increasingly large internal truncations of central Ntail residues, each ending immediately 
upstream of MoRE near the Ntail C-terminus. Characterization of these constructs revealed the 
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role of Ntail in RdRp bioactivity in biochemical assays and morbilliviral fitness and growth 
kinetics in cell culture including CDV viral pathogenesis analysis. To probe an effect of Ntail 
truncations on viral pathogenesis, recombinant CDVs were analyzed in a lethal CDV/ferret 
model of morbillivirus disease. The recombinant viruses displayed different stages of attenuation 
ranging from ameliorated clinical symptoms to complete survival of infected animals, depending 
on the molecular nature of the Ntail truncation. Reinfection of surviving animals with pathogenic 
CDV revealed robust protection against a lethal challenge. The highly attenuated virus was 
genetically stable after ex vivo passaging and recovery from infected animals. Mechanistically, 
gradual viral attenuation coincided with stepwise-altered viral transcriptase activity in infected 
cells. These results identify the central Ntail section as a determinant for viral pathogenesis and 
establish a novel platform to engineer gradual virus attenuation for next-generation 
paramyxovirus vaccine design. 
We can summarize our study using the following model: 
 
Figure 21: Models of the mechanistic basis for the impact of Ntail on RdRp transcriptase 
activity.  
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 (model kindly provided by J. Sourimant – from Institute for Biomedical Sciences, Georgia State 
University) 
Upon initialization at the terminal promoter, the viral P-L polymerase complex first synthesizes a 
short Leader RNA (as shown in the figure 21: L is depicted in grey, P tetramers are shown in 
blue, orange and yellow circles at the end of Ntails represent MoRE and box3, respectively). 
Encapsidation of this Leader by N proteins switches the polymerase into replicase mode in which 
it ignores intergenic junctions and generates a full-length encapsidated copy of the viral genome. 
If not encapsidated, Leader is released by the polymerase complexes, which then travels in 
transcriptase mode towards the first gene start site and proceeds generating viral mRNAs. In 
either case, advancing of the RdRp along the genome involves the release of existing N-
MoRE/P-L interactions, Ntail reordering in front of the polymerase complex, and local de-
encapsidation of the viral RNA. A) In the first model, removal of the central Ntail section may 
reduce the encapsidation efficiency of the nascent Leader RNA, causing a transcriptase bias of 
the polymerase complex (thick horizontal arrow). B) Alternatively, elimination of the central 
Ntail section may reduce the need for local Ntail ordering ahead of the advancing polymerase 
complex, narrowing the time window available for Leader encapsidation by accelerating Leader 
transcription (staggered horizontal arrows) promoting polymerase switch to transcriptase mode.  
 
The significance of this study can be summarized as follows: 
New Vaccination Strategy: The first attenuated live vaccine for MeV was developed by 
adaptation of Edm strain to chick embryo fibroblasts but this vaccine was further passaged to 
develop a more attenuated and non-reactogenic vaccine (137). Limitations to MeV vaccines do 
exist including the potential for interference from maternal antibodies in young children 
 69 
preventing a strong protective response (138, 139). This has led to the re-emergence of MeV 
infection in highly vaccinated populations (140). 
 
 Different individual point mutations have also been tested to engineer attenuation to 
develop new vaccine strategies. But, this kind of strategy always has the risk of spontaneous 
reversion to its pathogenic form. To overcome this, DNA vaccines have been proposed as an 
alternative vaccination strategy for infants and in vivo studies recently. These have demonstrated 
their potential utility (141, 142) as they elicit strong protective humoral and cell-mediated 
immune response (143, 144). Although such vaccines are effective and relatively inexpensive to 
produce, problems associated with vaccination regime and delivery routes need to be resolved. 
 
      With the help of an attenuation strategy, we can engineer the unstructured Ntail section in 
order to modulate the varying degrees of attenuation to develop the next-generation vaccines. 
This attenuation strategy by Ntail truncation may also be applicable to various other 
paramyxovirus candidates as we have shown proof-of-concept in minireplicon systems for 
highly pathogenic NiV. The main advantage of using an attenuation strategy for the development 
of vaccines for closely related Paramyxoviruses is that it will be highly unlikely for the virus to 
revert back and turn pathogenic as it cannot de novo synthesize the deleted residues of the 
nucleoprotein. This kind of tunable attenuation can be very helpful for the development of an 
efficient vaccines against highly pathogenic members of this family that do not have effective 
prophylactic measures to date. 
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Revising the current model of polymerase recruitment and progress along the template and 
protein interactions: Our current understanding of Paramyxoviridae replication and how N, P 
and L proteins interact is incomplete. It is also critically important to understand and revise the 
current model of the proposed interactions between the proteins, in order to aid in the 
development of effective antiviral treatments. In our study, N proteins with large tail truncations 
remained bioactive in mono- and polycistronic minireplicon assays and supported efficient 
replication of recombinant viruses. Bioactivity of Ntail mutants extended to N proteins derived 
from highly pathogenic Nipah virus. We have hypothesized the predicted location of candidate 
compensatory mutation to the NΔ425-479 truncation, thereby suggesting the cross-talk of N-core 
and N-tail, in a model of the CDV RNP assembly. As shown in the figure 21, the truncation in 
the central Ntail section may allow acceleration of the advancing polymerase complex. This may 
reduce the time window available for encapsidation and may accelerate transcription.  
 
Mechanistic role of the central section of the N-tail: Knowledge of the replication machinery 
and the protein-protein interactions involved is very critical for the study and development of 
effective prophylactic/therapeutic strategies. This study helped us to gain deeper insights into 
their role in RdRp-mediated transcription and replication. Although the MeV N-tail is considered 
dispensable for polymerase activity, it is considered to be important for stabilization of the P-L 
complex onto RNP template (80) By making truncations in the central section of the N-tail, we 
altered the molecular nature of the interface between N-terminal Ntail residues and the RNP 
rungs. We noted two different degrees of viral attenuation, depending on the extent of the central 
CDV-Ntail truncation. By analyzing the quantitations of viral RNA populations present in these 
virus-infected cells, we observed a single versus double hit effect of the individual modifications 
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in the N-tail on polymerase function. The first hit is termed by showing a partial shift of 
polymerase activity from replicase to transcriptase mode compared to the parental recCDV 
strain. This change was seen in cells infected with either CDV mutant virus. In addition to the 
first hit, the recCDV NΔ441-479 recombinant also showed a second hit. The second hit shows a 
relative higher proportion of polycistronic viral message, which directly affects the gradient of 
functional viral mRNAs available in infected cells.  
 
      Currently, we cannot conclude whether these intrinsically disordered N-tails have developed 
recently or whether they were present in the N proteins of an ancestral mononegavirales. As 
there is an experimental confirmation that N-tail MORE can be readily moved into 
paramyxovirus Ncore, we assume that ancestral nucleoproteins were tailless and then gradually 
the N-tail developed in the modern viruses. As the N-tails developed, the nucleoproteins gained 
novel N functions such as interactions with host cell factors, to fine-tune viral polymerase 
activities, to regulate the natural paramyxovirus transcription gradient of mRNA synthesis. These 
functions seem to explain the evolution of the unstructured Ntail region.  
 
To summarize, we have confirmed that the truncations in the CDV central N-tail section are 
possible. The additional CDV central N-tail truncated NΔ425 substitutions do not affect RdRp 
activity. But, the central N-tail truncated mutant viruses closer to the RNP leads to accumulation 
of some compensatory mutations. We are further investigating the role of a hypothesized motif 
present in the central section of the CDV-N-tail that may regulate the viral activity. This will 
give us a better understanding of the repeated serine residues (possibly a motif) present in the 
central section of the N-tail and help us to definitely revise the current model of RdRp 
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recruitment and progress along the template. The double-substituted aspartic-acid (CDV-
NΔ425_DERD) does not hamper virus rescue but CDV-NΔ425_SERS only grows further with 
compensatory mutation in box 1 (so far seen). The negative charges/S421 phosphorylation at the 
region near RNP in the N-tail seems to be important for viral replication. I hypothesize that the 
421S residue is phosphorylated and this phosphorylated site between the box 1 and 2 and the 
presence of all the conserved boxes are main factors important for efficient CDV replication.  
 
The modeling of the cross-talk between morbilliviral N-tail residues and the N-core loop region 
seems to be very interesting. Further experiments are needed to characterize the role of 
compensatory mutations in central unstructured N-tail mutants closer to RNP in the future. The 
effect of compensatory mutations in terms of minireplicon activity, viral fitness, viral 
pathogenesis and transcription/replication balance needs to be further determined. In the future, 
the influence of charges and/or S421 phosphorylation on the RNP surface needs to be identified. 
It may be possible that this is applicable only to the interferon-negative Vero-dog SLAM cells 
and that the actual hosts (carnivores) show different results. Further in-vivo experiments are 
needed to prove this. 
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